Trials / Completed
CompletedNCT05431543
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- LENZ Therapeutics, Inc · Academic / Other
- Sex
- All
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aceclidine+Brimonidine combination ophthalmic solution | LNZ101-combination ophthalmic solution |
| DRUG | Aceclidine ophthalmic solution | LNZ100- aceclidine ophthalmic solution |
| DRUG | Vehicle proprietary ophthalmic solution | Proprietary Vehicle ophthalmic solution |
Timeline
- Start date
- 2022-08-06
- Primary completion
- 2022-12-14
- Completion
- 2022-12-14
- First posted
- 2022-06-24
- Last updated
- 2024-09-05
- Results posted
- 2024-09-05
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05431543. Inclusion in this directory is not an endorsement.